Biocad to launch first drug for treatment of ankylosing spondylitis in Russia

7 May 2024

The first drug for the treatment of ankylosing spondylitis has been registered in the Russian Federation, according to the country’s Ministry of Health and local media reports.

According to an official spokesman of the Ministry, the conducted clinical trials have shown the effectiveness of the drug and its safety, which creates conditions for the beginning of its commercial production. The name of the drug has not been identified.

The drug was developed by scientists from the Russian Pirogov National Research Medical University and experts of the Russian drugmaker Biocad, that will produce the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK